The β3 adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes

European Neuropsychopharmacology

Volumn 20, Issue 10, 2010, Pages 704-713

  Tamburella, Alessandra ^a   Micale, Vincenzo ^a   Leggio, Gian Marco ^a   Drago, Filippo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

3 adrenoceptors; Amibegron; Forced swim test; Neurotrophic factors; Restraint stress

Indexed keywords

[[7 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO] 5,6,7,8 TETRAHYDRO 2 NAPHTHYL]OXY]ACETIC ACID ETHYL ESTER; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOMIPRAMINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; AMIBEGRON; ANTIDEPRESSANT AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG MECHANISM; FORCED SWIMMING TEST; IMMOBILIZATION STRESS; MALE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STRESS; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; DEPRESSION; DRUG EFFECT; HIPPOCAMPUS; MENTAL STRESS; METABOLISM; PHYSIOLOGY; SWIMMING;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BCL-2-ASSOCIATED X PROTEIN; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CLOMIPRAMINE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DEPRESSION; HIPPOCAMPUS; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; STRESS, PSYCHOLOGICAL; SWIMMING; TETRAHYDRONAPHTHALENES;

EID: 77956179997     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.04.006     Document Type: Article

References (60)

1. Arunrut T., Alejandre H., Chen M., Cha J., Russo-Neustadt A. Differential behavioral and neurochemical effects of exercise, reboxetine and citalopram with the forced swim test. Life Sci. 2009, 84:584-589.
2. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
3. Briones-Aranda A., Lopez-Rubalcava C., Picaro O. Influence of forced swimming-induced stress on the anxiolytic-like effect of 5HT(1A) agents in mice. Psychopharmacology 2002, 162:147-155.
4. Chaki S., Nakazato A., Kennis L., Nakamura M., Mackie C., Sugiura M., Vinken P., Ashton D., Langlois X., Steckler T. Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol. 2004, 485:145-158.
5. Chen A.H., Shirayama Y., Shin K.H., Neve R.L., Duman R.S. Expression of the cAMP response element binding protein (CREB) in hippocampus produces antidepressant effect. Biol. Psychiatry 2001, 49:753-762.
6. 3 adrenoceptor agonist SR58611A (amibegron) on serotoninergic and noradrenergic transmission in the rodent: relevance to its antidepressant/anxiolytic-like profile. Neuroscience 2008, 156:353-364.
7. Consoli D., Fedotova J., Micale V., Sapronov N.S., Drago F. Stressors affect the response of male and female rats to clomipramine in a model of behavioral despair (forced swim test). Eur. J. Pharmacol. 2005, 520:100-107.
8. 3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?. Eur. J. Pharmacol. 2007, 573:139-147.
9. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2002, 2:647-656.
10. Cryan J.F., Page M.E., Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology 2005, 182:335-344.
11. Czéh B., Lucassen P.J. What causes the hippocampal volume decrease in depression? Are neurogenesis, glial changes and apoptosis implicated?. Eur. Arch. Psychiatry Clin. Neurosci. 2007, 257:250-260.
12. Drago F., Nicolosi A., Micale V., Lo Menzo G. Placebo affects the performance of rats in models of depression: is it a good control for behavioural experiments?. Eur. Neuropsychopharmacol. 2001, 11:209-213.
13. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
14. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 1997, 54:597-606.
15. Duman R.S., Malberg J., Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 1999, 46:1181-1191.
16. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 2006, 59:1116-1127.
17. Eisch A.J., Bolaños C.A., de Wit J., Simonak R.D., Pudiak C.M., Barrot M., Verhaagen J., Nestler E.J. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol. Psychiatry 2003, 54:994-1005.
18. Kosten T.A., Galloway M.P., Duman R.S., Russell D.S., D'Sa C. repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology 2008, 33:1545-1558.
19. Lenard N.R., Gettys T.W., Dunn A.J. Activation of beta2- and beta3- adrenergic receptors increases brain tryptophan. J. Pharmacol. Exp. Ther. 2003, 305:653-659.
20. Lindsten T., Zong W.X., Thompson C.B. Defining the role of the Bcl-2 family of proteins in the nervous system. Neuroscientist 2005, 11:10-15.
21. Lirussi F., Rakotoniaina Z., Madani S., Goirand F., Breuiller-Fouché M., Leroy M.J., Sagot P., Morrison J.J., Dumas M., Bardou M. ADRB3 adrenergic receptor is a key regulator of human myometrial apoptosis and inflammation during chorioamnionitis. Biol. Reprod. 2008, 78:497-505.
22. Lucassen P.J., Müller M.B., Holsboer F., Bauer J., Holtrop A., Wouda J., Hoogendijk W.J., De Kloet E.R., Swaab D.F. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am. J. Pathol. 2001, 158:453-468.
23. Lucassen P.J., Fuchs E., Czéh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol. Psychiatry 2004, 55:789-796.
24. Luo C., Xu H., Li X.M. Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res. 2004, 1025:194-202.
25. Luo C., Xu H., Li X.M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Res. 2005, 1063:32-39.
26. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J. Neurosci. 2000, 20:9104-9110.
27. Manier D.H., Shelton R.C., Sulser F. Noradrenergic antidepressants: does chronic treatment increase or decrease nuclear CREB-P?. J. Neural Transm. 2002, 109:91-99.
28. Manji H.K., Chen G. PKC, MAP kinases and the Bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry 2002, 7:S46-S56.
29. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K.A., Gray N., Zarate C.A., Charney D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry 2003, 53:707-742.
30. McEwen B.S. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005, 54:20-33.
31. Micale V., Arezzi A., Rampello L., Drago F. Melatonin affects the immobility time of rats in the forced swim test: the role of serotonin neurotransmission. Eur. Neuropsychopharmacol. 2006, 16:538-545.
32. Micale V., Scapagnini G., Colombrita C., Mazzola C., Alkon D.L., Drago F. Behavioral effects of dietary cholesterol in rats tested in experimental models of mild stress and cognition tasks. Eur. Neuropsychopharmacol. 2008, 18:462-471.
33. Micale V., Tamburella A., Leggio G.M., Mazzola C., Li Volsi V., Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol. Biochem. Behav. 2008, 90:463-469.
34. Monteggia L.M., Barrot M., Powell C.M., Berton O., Galanis V., Gemelli T., Meuth S., Nagy A., Greene R.W., Nestler E.J. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. USA 2004, 101:10827-10832.
35. Murray F., Hutson P.H. Hippocampal Bcl-2 expression is selectively increased following chronic but not acute treatment with antidepressants, 5-HT(1A) or 5-HT(2C/2B) receptor antagonists. Eur. J. Pharmacol. 2007, 569:41-47.
36. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 1995, 15:7539-7547.
37. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP element binding protein (CREB) in rat hippocampus. J. Neurosci. 1996, 16:2365-2372.
38. 3-adrenoceptor agonist amibegron in an animal model of depression. Pharmacol. Biochem. Behav. 2008, 89:36-45.
39. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
40. Porsolt R.D., Bertin A., Jalfre M. "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol. 1978, 51:291-294.
41. Rademacher D.J., Meier S.E., Shi L., Ho W.S.V., Jarrahian A., Hillard C.J. Effects of acute and repeated restraint stress on endocannabinoids content in the amygdala, ventral striatum, and medial prefrontal cortex in mice. Neuropharmacology 2008, 54:108-116.
42. Rénéric J.P., Bouvard M., Stinus L. In the rat forced swimming test, chronic but not subacute administration of dual 5-HT/NA antidepressant treatments may produce greater effects than selective drugs. Behav. Brain Res. 2002, 136:521-532.
43. Rodriguez M., Carillon C., Coquerel A., Le Fur G., Ferrara P., Caput D., et al. Evidence for the presence of beta 3-adrenergic receptor mRNA in the human brain. Brain Res. Mol. Brain Res. 1995, 29:369-375.
44. Schaeffer P., Bernat A., Arnone M., Manara L., Gallas J.F., Dol-Gleizes F., Millet L., Grosset A., Herbert J.M. Effect of SR58611A, a potent beta-3 adrenoceptor agonist, on cutaneous wound healing in diabetic and obese mice. Eur. J. Pharmacol. 2006, 529:172-178.
45. Schmidt H.D., Duman R.S. The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav. Pharmacol. 2007, 18:391-418.
46. Shirayama Y., Chen A.C.H., Nakagawa S., Russel R.S., Duman R.S. Brain derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 2002, 22:3251-3261.
47. Simiand J., Keane P.E., Guitard J., Langlois X., Gonalons N., Martin P., Bianchetti A., Le Fur G., Soubrié P. Antidepressant profile in rodents of SR58611A, a new selective agonist for atypical beta-adrenoceptors. Eur. J. Pharmacol. 1992, 219:193-201.
48. Smith M.A., Makino S., Kvetnansky R., Post R.M. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J. Neurosci. 1995, 15:1768-1777.
49. 3-adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 2008, 33:574-587.
50. Stemmelin J., Cohen C., Yalcin I., Keane P., Griebel G. Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. Behav. Brain Res. 2010, 206:310-312.
51. Strosberg A.D. Structure and function of the beta 3-adrenergic receptor. Annu. Rev. Pharmacol. Toxicol. 1997, 37:421-450.
52. Summers R.J., Papaioannou M., Harris S., Evans B.A. Expression of beta 3-adrenoceptor mRNA in rat brain. Br. J. Pharmacol. 1995, 116:2547-2548.
53. Tamburella A., Micale V., Navarria A., Drago F. Antidepressant properties of the 5-HT4 receptor partial agonist, SL65.0155: behavioral and neurochemical studies in rats. Prog. Neuropsychopharm. Biol. Psych. 2009, 33:1205-1210.
54. Teixeira R.M., De Lima T.C.M. Involvement of tachykinin NK1 receptor in the behavioral and immunological responses to swimming stress in mice. Neuropeptides 2003, 37:307-315.
55. Tonello C., Giordano A., Cozzi V., Cinti S., Stock M.J., Carruba M.O., Nisoli E. Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats. FEBS Lett. 1999, 442:167-172.
56. Warner-Schmidt J.L., Duman R.S. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 2006, 16:239-249.
57. Warner-Schmidt J.L., Duman R.S. VEGF is an essential mediator for the neurogenic and behavioral actions of antidepressants. Proc. Natl. Acad. Sci. USA 2007, 104:4647-4652.
58. Warner-Schmidt J.L., Duman R.S. VEGF as a potential target for therapeutic intervention in depression. Curr. Opin. Pharmacol. 2008, 8:14-19.
59. Xu H., Richardson J.S., Li X.M. Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology 2003, 28:53-62.
60. Zhao H., Xu H., Xu X., Young D. Predatory stress induces hippocampal cell death by apoptosis in rats. Neurosci. Lett. 2007, 421:115-120.